^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    aclarubicin

    i
    Other names: MA144-A1, MA144 A1, MA144A1
    Company:
    Generic mfg.
    Drug class:
    DNA intercalator
    Related drugs:
    3d
    Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    3d
    Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    4d
    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Dec 2027 --> Sep 2027
    Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin
    1m
    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov)
    P2, N=160, Recruiting, Chinese PLA General Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    2ms
    PD1-VEN-CAG: PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL (clinicaltrials.gov)
    P3, N=40, Active, not recruiting, Fujian Medical University Union Hospital
    New P3 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • aclarubicin
    2ms
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=37, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P1/2 trial
    |
    cyclophosphamide • vincristine • prednisone • aclarubicin
    2ms
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK negative
    |
    cyclophosphamide • vincristine • prednisone • aclarubicin
    2ms
    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin
    3ms
    Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=200, Recruiting, Chinese PLA General Hospital | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • fludarabine IV • aclarubicin
    3ms
    Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=112, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P1/2 trial
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Venclexta (venetoclax) • azacitidine • aclarubicin
    3ms
    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Chinese PLA General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Sep 2025
    Enrollment closed • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    4ms
    Diagnosis and management of rare acute erythroid leukemia with hemophagocytic lymphohistiocytosis: a case report. (PubMed, Front Oncol)
    Initial therapy with a decitabine-CAG (aclacinomycin, cytarabine, G-CSF)-venetoclax regimen failed to induce remission. Morphological complete remission was achieved after switching to a DAE (daunorubicin, cytarabine, etoposide) regimen...This case highlights the diagnostic and therapeutic complexities associated with the co-occurrence of AEL and HLH. Early identification of HLH as a potential complication in AEL is crucial, though outcomes remain dismal, emphasizing an urgent need for novel therapeutic strategies.
    Journal
    |
    CRP (C-reactive protein)
    |
    Venclexta (venetoclax) • etoposide IV • decitabine • daunorubicin • aclarubicin